Friday, July 3, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
DEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets PaidyesterdayENERGYThe Interconnect Loser: Why FERC's Co-Location Ruling Could Squeeze Merchant Nuclear Margins4 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet TailwindyesterdayHEALTHCAREGLP-1 Coverage Mandate: The Federal Obesity Drug Windfall for Lilly and Novo4 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big TechyesterdayENERGYVistra vs. Constellation: Same Nuclear Tax Credit, Very Different Downside if Congress Kills It4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is MovingyesterdayHEALTHCAREFDA Accelerated Approval Reform: The Vertex Model Every Biotech Wants4 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real MoneyyesterdayENERGYTalen Energy: The Merchant Nuclear Stock That Only Washington Can Break4 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending BoomyesterdayHEALTHCAREThe Medicare Drug Negotiation Trade: Who Gets Hurt When Washington Sets the Price4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger MarketyesterdayENERGYBWXT: The Naval Nuclear Contractor Riding a Civilian Policy Wave4 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company ForeveryesterdayENERGYThe NRC Discount Helps Oklo More Than NuScale — Because NuScale Already Paid Full Price4 weeks agoDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stock2 days agoCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producers2 days agoENERGYForget Which Reactor Wins — GE Vernova Owns the Queue4 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watch2 days agoCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Political2 days agoCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spending2 days agoENERGYCentrus vs. Cameco: Washington's Russian Uranium Ban Splits the Nuclear Fuel Chain4 weeks agoDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Game2 days agoENERGYThe HALEU Contract Nobody Prices In4 weeks agoDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risk3 days agoCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade3 days agoENERGYWhy Constellation (CEG) Is Really a Policy Stock, Not a Utility Stock4 weeks agoDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet4 days agoCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners4 weeks agoDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX4 days agoCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It4 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation4 days agoENERGYWillow Isn't an Oil Play. It's an Interior Department Play.4 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream4 days agoCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade3 weeks agoDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides5 days agoENERGYWho Gets Exposed When the SPR Refill Never Happens3 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It5 days agoENERGYWashington Fixed the LNG Permit. It Can't Fix a County Courthouse in Guilford County.3 weeks agoDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine6 days agoENERGYThe Jones Act's Hidden LNG Winner: Foreign Tankers, Not U.S. Shippers, Cash In3 weeks agoDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order6 days agoCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model3 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program6 days agoENERGYHalliburton vs. SLB: Who Actually Cashes In on Methane Compliance3 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes6 days agoENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.3 weeks agoDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenlylast weekTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oillast weekTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differentlylast weekENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog3 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivotlast weekENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners3 weeks agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Throughlast weekTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock3 weeks agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Storylast weekENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll3 weeks agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguiselast weekTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First3 weeks agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratoslast weekTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Betlast weekDEFENSEThe Refueling Line Nobody Prices Into BWXT3 weeks agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price3 weeks agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast weekENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers3 weeks agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washingtonlast weekTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two3 weeks agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hublast weekDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat2 weeks agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spendinglast weekENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom2 weeks agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Primelast weekDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch2 weeks agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alivelast weekDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes2 weeks agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AIlast weekDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization2 weeks agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus2 weeks agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear2 weeks agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors2 weeks agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch2 weeks agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money2 weeks agoDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop2 weeks agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One2 weeks agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks ago
That's your last free article this week. Create a free account for 2 a week — or go Pro for everything.Go Pro →
Healthcare

AbbVie's Post-Humira Playbook: Why Patent-Cliff Policy Is the Real Story

The Skyrizi/Rinvoq pipeline narrative gets the headlines, but the pace of Humira's collapse — and who profits from it — is being set by FDA interchangeability rulings and state pharmacist-substitution statutes, not by AbbVie's lab.

Image: Money Racket
By at Money Racket · Apr 18, 2026

Wall Street tells AbbVie's story as a pipeline story: Skyrizi and Rinvoq growing fast enough to outrun Humira's decline. That framing misses the actual throttle. Under the Biologics Price Competition and Innovation Act (BPCIA), a biosimilar doesn't just need FDA approval to compete — it needs an interchangeability designation to be swapped for Humira at the pharmacy counter without a new prescription. And whether that swap actually happens depends on a second, less-watched layer: state pharmacy practice laws that decide if and how pharmacists execute the substitution. That combination — federal designation plus state execution — is a policy clock, not a science clock, and it has already re-rated one of the largest revenue bases in pharma. AbbVie's U.S. Humira sales have fallen roughly 38% since biosimilars entered in 2023, and the FDA's Purple Book now lists ten approved adalimumab biosimilars, most carrying interchangeable status. Every new interchangeability ruling and every state that tightens or loosens substitution rules moves billions in prescription volume — a lever AbbVie itself doesn't hold.

Who cashes in:

  • Pfizer (PFE) — Abrilada is FDA-designated interchangeable, giving Pfizer's biosimilars unit automatic pharmacy-level substitution rights in states with permissive laws, converting Humira's patent cliff directly into biosimilar volume.
  • Novo Nordisk (NVO) — Via its Organon partnership network in the broader biosimilar/adjacent specialty-pharma ecosystem, Novo benefits less directly here, but the read-through is real: as payers get comfortable forcing interchangeable substitution on immunology biologics, the same PBM playbook (formulary-driven switching) is being rehearsed for GLP-1 follow-on competition — precedent that matters as Novo's own moat gets tested.
  • Bristol Myers Squibb (BMY) — With psoriasis/immunology assets exposed to the same payer substitution mechanics, BMY benefits indirectly as PBMs standardize adalimumab-class switching protocols that lower the switching-cost barrier for the entire immunology category, softening one advantage AbbVie has used to defend Skyrizi/Rinvoq share.
The pace of Humira's collapse isn't set in AbbVie's lab — it's set in the Purple Book and in fifty statehouses.

Who is exposed:

  • AbbVie (ABBV) — Every additional state that adopts an interchangeability-triggered automatic-substitution statute, and every new adalimumab interchangeable approval added to the Purple Book, accelerates the Humira base AbbVie must replace with Skyrizi/Rinvoq — a substitution rate the company cannot lobby away once FDA has ruled.
  • Eli Lilly (LLY) and Viking Therapeutics (VKTX) are not direct casualties here, but both sit downstream of the same regulatory template: BPCIA-style interchangeability plus state substitution law is the exact mechanism payers want to extend to GLP-1s once follow-on competition arrives, meaning today's Humira playbook is tomorrow's pricing risk for incretin franchises.

The play: Don't trade AbbVie on Skyrizi/Rinvoq launch data — trade it on the Purple Book. Each new interchangeable adalimumab designation and each state substitution-law update is a public, dated event that reprices the erosion curve before AbbVie's own quarterly print catches up. Watch FDA's ongoing interchangeability determinations and state legislative sessions addressing biosimilar substitution — that's the calendar that actually governs the stock, not AbbVie's R&D roadmap.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →